Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
Learn more: Slow-release hydrogel aids immunotherapy for cancer
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”Cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- AUA 2024: Anticipating Developments in Metastatic Prostate Cancer Researchon May 10, 2024 at 2:29 pm
AUA 2024 offers valuable learning opportunities, including forums on advanced prostate cancer and instructional courses on the new AUA guidelines. In addition, new programs like P2s and Clinical ...
- Certain Immunotherapy Drugs Not Recommended for Pregnant Women With Canceron May 10, 2024 at 2:22 pm
When possible, immune checkpoint inhibitors should be avoided in pregnant women with cancer due to lung inflammation and possible miscarriage, researchers found.
- Direct measurement of the interaction between immune cells and cancer cells from a patient's biopsyon May 10, 2024 at 10:24 am
Researchers have unveiled a technology that promises to improve cancer treatment decisions based on a patient's biopsy. The pioneering biological research and development measures changes in immune ...
- Revolutionary mRNA Cancer Vaccine Shows Immense Promise in First-Ever Human Clinical Trialon May 10, 2024 at 8:56 am
In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine created at the University of Florida rapidly reprogrammed the immune system to target glioblastoma, the deadliest ...
- How ultrasound and microbubbles could deliver immunotherapy to the brainon May 9, 2024 at 10:44 am
Malignant primary brain tumors are the leading cause of cancer deaths among children and young adults with few therapeutic options. Treatments are limited by the blood–brain barrier, a unique ...
- Researchers discover benefits of adding immune-boosting agent to personalized cancer vaccineon May 9, 2024 at 9:18 am
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an ...
- Supercharging immune cells to battle blood cancer: Advances in cancer immunotherapyon May 9, 2024 at 6:51 am
Cancer has a profound impact on human life, and immune checkpoint therapy (ICT) has made remarkable strides in cancer treatment. However, ICT faces challenges such as low overall response rates and ...
- Supercharging immune cells to battle blood cancer: Breakthrough in cancer immunotherapyon May 8, 2024 at 5:00 pm
A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and phosphatidylserine (PS) significantly enhances the ability ...
- Can Vitamin D Improve Cancer Immunotherapy?on May 8, 2024 at 6:30 am
Your diet could impact your cancer treatment’s progress; a new preclinical study suggests more vitamin D could improve responses to checkpoint inhibitors.
- Study uncovers at least one cause of roadblocks to cancer immunotherapyon May 6, 2024 at 9:39 am
T cells—the body's foot soldiers against invaders, ranging from everyday infections to cancers—are integral to many successful immunotherapies. However, a frustrating factor is that immunotherapies do ...
via Bing News